FRANKFURT (Reuters) – AstraZeneca is still waiting for the go-ahead from the U.S. drug regulator to restart the clinical trial of its COVID-19 vaccine hopeful in the United States, Chief Executive Pascal Soriot said on Thursday.
“We are awaiting to hear their decision,” Soriot told a virtual World Economic Forum discussion.
(Reporting by Ludwig Burger; Editing by Caroline Copley)
